无疾病进展或治疗限制性毒性时停用抗PD-1抗体治疗晚期黑色素瘤的临床结局
这项学术性真实世界队列研究纳入欧洲和澳大利亚14家医疗中心的185例晚期黑色素瘤患者,患者在无疾病进展或治疗限制性毒性时主动停用帕博利珠单抗(167例)或纳武利尤单抗(18例)。停药后中位随访18个月,78%患者保持无进展;完全缓解患者疾病进展发生率低于部分缓解和疾病稳定患者。
要点
- 中位治疗时间12个月,停药时完全缓解117例(63%)、部分缓解44例(24%)、疾病稳定16例(9%)。
- 停药后中位随访18个月,78%患者保持无进展,中位至进展时间12个月。
- 疾病进展发生率在完全缓解患者中为14%,部分缓解为32%,疾病稳定为50%。
核心结论
- 在无治疗限制性毒性或疾病进展时停用抗PD-1治疗的晚期黑色素瘤真实世界队列中,抗PD-1治疗持续时间较临床试验短。
- 获得完全缓解且治疗超过6个月的患者停药后复发风险低。
- 最佳肿瘤缓解为部分缓解或疾病稳定的患者停药后进展风险较高,确定此类患者的最佳治疗持续时间值得进一步研究。
- 疾病进展时再次使用抗PD-1治疗可能使部分患者获得新的抗肿瘤活性。
研究设计与样本
- 学术性真实世界队列研究,纳入欧洲和澳大利亚14家医疗中心的185例晚期黑色素瘤患者。
- 患者在无疾病进展或治疗限制性毒性时主动停用帕博利珠单抗(167例)或纳武利尤单抗(18例)。
- 临床试验注册号NCT02673970。
主要发现
- 中位治疗时间12个月(范围0.7-43)。
- 停药时最佳客观肿瘤缓解:完全缓解117例(63%),部分缓解44例(24%),疾病稳定16例(9%),无 evaluable 疾病8例(4%)。
- 停药后中位随访18个月(范围0.7-48),78%患者保持无进展。
- 中位至进展时间12个月(范围2-23)。
- 疾病进展发生率:完全缓解患者14%,部分缓解患者32%,疾病稳定患者50%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Programmed cell death protein 1 (PD-1) blocking monoclonal antibodies improve the overall survival of patients with advanced melanoma but the optimal duration of treatment has not been established. PATIENTS AND METHODS: This academic real-world cohort study investigated the outcome of 185 advanced melanoma patients who electively discontinued anti-PD-1 therapy with pembrolizumab (N = 167) or nivolumab (N = 18) in the absence of disease progression (PD) or treatment limiting toxicity (TLT) at 14 medical centres across Europe and Australia. RESULTS: Median time on treatment was 12 months (range 0.7-43). The best objective tumour response at the time of treatment discontinuation was complete response (CR) in 117 (63%) patients, partial response (PR) in 44 (24%) patients and stable disease (SD) in 16 (9%) patients; 8 (4%) patients had no evaluable disease (NE). After a median follow-up of 18 months (range 0.7-48) after treatment discontinuation, 78% of patients remained free of progression. Median time to progression was 12 months (range 2-23). PD was less frequent in patients with CR (14%) compared with patients with PR (32%) and SD (50%). Six out of 19 (32%) patients who were retreated with an anti-PD-1 at the time of PD obtained a new antitumour response. CONCLUSIONS: In this real-world cohort of advanced melanoma patients discontinuing anti-PD-1 therapy in the absence of TLT or PD, the duration of anti-PD-1 therapy was shorter when compared with clinical trials. In patients obtaining a CR, and being treated for >6 months, the risk of relapse after treatment discontinuation was low. Patients achieving a PR or SD as best tumour response were at higher risk for progression after discontinuing therapy, and defining optimal treatment duration in such patients deserves further study. Retreatment with an anti-PD-1 at the time of progression may lead to renewed antitumour activity in some patients. CLINICAL TRIAL REGISTRATION: NCT02673970 (https://clinicaltrials.gov/ct2/show/NCT02673970?cond=melanoma&cntry=BE&city=Jette&rank=3).
引用
- Jansen YJL, Rozeman EA, Mason R, et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol. 2019. PMID: 30923820. doi:10.1093/annonc/mdz110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。